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Abstract
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Objective—The presence of circulating autoantibodies against phosphatidylethanolamine (PE)
has been shown to be positively associated with symptoms of antiphospholipid syndromes (APS).
However, the current ELISA-based tests for antiphosphatidylethanolmine (aPE) antibodies remain
inconsistent and controversial. The term PE refers to a collection of phospholipids that have
phosphorylethanolamine head group as a common structural feature, but can vary in fatty acids
with diverse physicochemical properties. The present study was to investigate, using synthetic
positionally symmetrical PE species as a model system, the impact of PE structural variations on
aPE ELISA.
Methods—Single and combinations of synthetic PE species, including 16:0 (fatty acid
length:degree of unsaturation), 18:0, 18:1, 20:4 and 22:6, were screened with ELISA using serum
samples from aPE patients and compared with chicken egg PE. There were a total of 37 aPE
patient serum samples, including 11 cofactor-independent IgM, 14 ABP-independent IgG and 12
ABP-dependent aPE serum samples (3 IgM, 8 IgG and 1 IgA). The ELISA conditions were
investigated for different isotypes and cofactor dependence. Based on the initial screening,
adjustments in phospholipid compositions were made for achieving optimal OD readings. Finally,
we isolated total IgG from aPE sera to validate different antigenic preferences.
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Results—The antigenic preference was different among immunoglobulin isotypes and between
cofactor-dependent versus cofactor-independent aPE antibodies. More specifically, 18:1 PE was a
preferred antigen for cofactor-dependent aPE, whereas 20:4 PE was the preferred antigen for
cofactor-independent IgG aPE. In contrast, cofactor-independent IgM aPE appeared to have a

Author of correspondence: Ming Zhao, PhD, Feinberg Cardiovascular Research Institute, Department of Medicine, Northwestern
University, 303 E. Chicago Avenue, Tarry 14-753, Chicago, IL, 60611. Phone: 312-503-3226. m-zhao@northwestern.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Hou et al.

Page 2

Author Manuscript

general preference for a more complex PE combination with longer fatty acids and a higher degree
of unsaturation.
Conclusion—The present data indicated that the outcome of aPE ELISA was dependent on the
composition and physicochemical properties of PE antigens. The discovery that aPE antibodies
may have different antigenic preferences could shed light on the nature of their binding
interactions.
Keywords
phosphatidylethanolamine; antiphosphatidylethanolamine antibodies; antiphospholipid syndrome
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The term antiphospholipid syndrome (APS) refers to a collection of autoimmune disorders
with thrombosis and/or recurrent pregnancy loss as main clinical manifestations (1–3).
Clinically established tests for APS currently include anticardiolipin, anti-β2-glycoprotein I,
and lupus anticoagulant (1–3). There are so called “non-criteria APS”, where
antiphospholipid antibodies have clinical symptoms consistent with APS but fall outside
current standard tests (4, 5). These autoantibodies, including antiphosphatidylethanolamine
(aPE), are being actively pursued in order to establish a complete diagnostic panel for APS
patients. In a number of clinical studies, aPE antibodies are shown to positively correlate
with symptoms of APS (6–21). While different antiphospholipid autoantibodies can coexist
in the same patient, aPE antibodies are sometimes the sole antibodies in patients with
symptoms of APS, suggesting aPE may be an independent etiological entity (16, 17).
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Enzyme-linked immunosorbent assays (ELISA) are widely practiced in the diagnosis for
APS. However, there lacks standardized ELISA protocols for aPE (22). In the current aPE
literature, various assay conditions have been documented from different laboratories.
Variations in aPE ELISA conditions include the source of PE (from bovine brain, egg yolk,
and bacteria), buffer compositions, blocking conditions and the presence of cofactors, where
it has been shown that different assay conditions may have a significant effect on the
outcome of ELISA tests (6, 23).
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The physicochemical properties of the antigen are an important determinant in ELISA. In
this respect, PE refers to a heterogeneous group of phospholipids that share
phosphorylethanolamine head group as a common structural feature, but differ in fatty acid
compositions (24). It has been well documented that the fatty acids of PE species can affect
the surface topology, fluidity and structural organization of PE membranes (25–27). The fact
that PE extracted from different natural sources produce variable ELISA readout is
indicative of a potential impact of the physical composition of the antigen on the reactivity
of aPE antibodies (28–30). Whether specific PE species may contribute to the interactions
with aPE antibodies remain largely unexplored and undefined.
The goal of this study was to examine the impact of PE compositions on the performance of
aPE ELISA using single and mixtures of synthetic PE species, based on a prior report which
demonstrated the feasibility using a simple two-component system (31). The present study
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involved positionally symmetrical PE species, with variable fatty acid length and the degree
of unsaturation. Our data indicated that the ELISA reactivity of aPE is dependent on the
composition of PE species and there is a preference of specific PE species based on the
antibody isotype and cofactor dependence.

Methods
Patient sera
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The study was approved by the Northwestern University Institutional Review Board and was
conducted under NIH guidelines. The patient serum samples were kind gifts from Dawn R.
Wagenknecht, M.S., and Nathalie Bardin, M.D., and the selected samples were positive for
aPE antibodies when tested by the HLA-Vascular Biology Laboratory at Franciscan St.
Francis Health, Indianapolis and Service d’Immunologie du Pr. Mège, Hôpital de la
Conception, Marseille, France, respectively. There were a total of 37 patient serum samples
included in this paper, which included 11 cofactor-independent IgM aPE sera, 14 ABPindependent IgG aPE sera and 12 ABP-dependent aPE serum samples (3 IgM, 8 IgG and 1
IgA).
Chemicals and reagents
All of the phospholipids used in this paper were purchased from Avanti polar lipids, which
included 16:0 PE (cat# 850705X); 18:0 PE (cat# 850715X); 18:1 PE (cat# 850725C), 20:4
PE (cat# 850800C); 22:6 PE (cat# 850797C); and egg PE (cat# 840021C).
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Pooled normal human sera, BSA and phosphatidylserine (PS) were purchased from SigmaAldrich. ABP was a kind of gift from Dr. Dawn R. Wagenknecht. Both BSA and ABP were
dissolved in 1X PBS and filtered with a 0.22 micron syringe filter before use. Anti-human
IgG (Cat# A9544), IgM (Cat# A3275) and IgA (cat# A9669) alkaline phosphatase and pnitrophenyl phosphate liquid substrate system (cat# N7656) were obtained from SigmaAldrich. NAb™ protein A/G spin kit (Cat# 89950) was obtained from Thermo Fisher
Scientific.
aPE ELISA

Author Manuscript

Each of the different PE preparations that were in chloroform was diluted in ethanol and
loaded in 96-well plate (Thermo Fisher Scientific, Cat# 12565138). The plate was dried in a
desiccator overnight and was blocked with 10% BSA for one hour on the platform shaker.
The blocking buffer was removed by aspiration and the plate was left in liquid nitrogen
vapor for 10 minutes. Each of the patient serum samples was diluted 100 times in 10% BSA
for cofactor-independent samples or in 10% ABP for cofactor-dependent samples. Fifty µl of
the dilute was loaded in each well of 96 well plate, and the plate was left on the platform
shaker for one hour. The plate was washed three times with PBS and 50 µl of alkaline
phosphatase-conjugated anti-IgG, IgM or IgA was added. After incubated for 1 hour and
washing three times with PBS, the plate was reacted with pnitrophenyl phosphate substrate.
The optical density at 405 was measured when the OD value of the positive samples reached
1.0. The ELISA for each sample was performed in triplicates.
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Total IgG was isolated from patient serum by using NAb™ protein A/G spin kit. Briefly,
NAb™ column was equilibrated with IgG binding buffer (100 mM phosphate, 150 mM
sodium chloride, pH 7.2) and incubated with normal control or patient serum for 15 minutes.
The total IgG was eluted with low pH elution buffer, and was immediately mixed with
neutralization buffer (1M Tris-HCl, pH8.5). The total IgG was dialyzed against PBS and
stored at −80°C for later use.

Result
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In the present study, we investigated the impact on aPE ELISA using a series of synthetic
positionally symmetrical PE species. These PE species, including 16:0 PE, 18:0 PE, 18:1
PE, 20:4 PE and 22:6 PE, are commercially available as individual chemically defined
products.
The effect and optimization of synthetic phospholipid compositions on the ELISA
performance of cofactor independent IgM aPE
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ELISA data using single and combinations of synthetic PE to detect cofactor-independent
aPE IgM reactivity in human patient serum samples is shown in Figure 1. The results
indicated that PE species with longer fatty acid tails with a greater degree of unsaturation
(for example 20:4 PE and 22:6 PE) tend to have a better performance (Figure 1,
formulations 2-6). Comparatively, single PE species with shorter fatty acid tails and a lower
degree of unsaturation had inferior performance than egg PE (Figure 1, formulations 2-4);
however, single PE species with longer fatty acid tails and a greater degree of unsaturation
could approach or exceed the ELISA OD readings obtained with egg PE as antigen (Figure
1, formulations 5 and 6). Additionally, the combinations consisting of one saturated and one
unsaturated PE species can have a comparable or a higher OD reading than either one of the
two individually (Figure 1, formulation 7 versus 2 and 3; formulation 8 versus 2 and 5;
formulation 9 versus 2 and 6; formulation 10 versus 3 and 4; formulation 11 versus 3 and 5,
formulation 12 versus 3 and 6). The compositions consisting of two PE species, with one
saturated and one unsaturated, can have a higher OD reading than egg PE when the
unsaturated PE species contains longer fatty acid tails with a greater degrees of unsaturation
(Figure 1, formulations 8, 9, 11 and 12). Furthermore, a combination of a greater variety of
PE species, four or five species, tends to have an even higher OD readings (Figure 1,
formulations 13-16), being better than single PE species and combinations of two PE
species, and significantly higher than egg PE.
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Next, we examined the ELISA performance of different PE compositions by varying the
contents of saturated PE species from 0 to 80%. We determined that a higher ELISA
performance was achieved when the content of saturated PE species was relatively low,
between 0 to 40% (Figure 2, formulation 2-6, 9-13), where these formulations significantly
and consistently had higher OD readings than egg PE. When the percentage of saturated PE
species was too high (Figure 2, formulations 7-8, 14-15), it was accompanied with
diminished OD readings.
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Based on the data in Figure 2, we fixed the saturated PE species in the formulation at 20% or
10%, and investigated the impact of variations among the remaining unsaturated PE species
(Figure 3). In these studies, the content of unsaturated PE species, which accounted for 80 or
90% of the formulations, were varied so that the ratios among 18:1 PE, 20:4 PE and 22:6 PE
were 1:1:1, 1:3:0, 1:0:3, 1:5:0, 1:0:5, 1:2:3, and 1:3:2 (Figure 3, formulations 2-8 and 9-15
for 20% or 10% of saturated PE species, respectively). For these studies, we determined that
overall, the formulations with 20% saturated PE species were generally superior to 10%, and
that variations in the ratios among the unsaturated PE species did not have a dramatic impact
on ELISA performance.
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Based on the results in Figure 3, after selecting a formulation (20% 18:0 PE, 13.3% 18:1 PE,
39.9% 20:4 PE, and 26.6% 22:6 PE) among the candidates that gave similarly optimized
ELISA performance, we tested the impact of the amount of coating material on ELISA
performance (Figure 4). As shown in Figure 4B, the optimal amount of coating was in the
range from 0.25 to 1µg per well in a 96 well ELISA plate. When the coating material was
too little (0.125 µg per well) or too much (2 µg per well or greater), it tended to adversely
affect the OD readings.
After selecting an optimal synthetic PE composition as a kit formulation, we conducted a
head-to-head comparison on the ELISA performance with egg PE using 11 cofactorindependent aPE IgM patient serum samples. As shown in Figure 5, the current kit
formulation consistently and significantly led to higher OD readings than egg PE in ELISA
(P = 0.006, n = 11). It was noteworthy that in multiple cases, the OD values of the ELISA
was improved by 100% to more than 400%.
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The effect and optimization of synthetic phospholipid compositions on the ELISA
performance of cofactor independent IgG aPE
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Figure 6 demonstrated the relative ELISA performance against egg PE from single and
combinations of synthetic PE species for detecting cofactor-independent aPE IgG reactivity.
The results indicated, somewhat unexpectedly, that for a representative aPE serum sample,
the single 20:4 PE (Figure 6, formulation 5) had the highest OD value, which was nearly 14
folds greater than egg PE on a representative patient serum sample. A number of other
formulations of synthetic PE (Figure 6, formulations 4, 6, 7, 11, 14, 15 and 16) also had
significantly higher OD values than egg PE. It appeared that when the combination contains
a higher percentage of 20:4 PE, it had a greater tendency to result in better sensitivity than
egg PE, which indicated 20:4 PE may be an important component in the PE formulations.
The inclusion of PE species with longer fatty acid tails with a greater degree of unsaturation
(for example 22:6 PE) also appeared to result in improved ELISA results compared to egg
PE.
Based on these results, we conducted a head-to-head study between the 20:4 PE and egg PE
for detecting the aPE reactivity among 14 cofactor-independent IgG patient serum samples
(Figure 7). The data indicated that most of patient serum samples having high aPE reactivity
on egg PE had even stronger aPE reactivity on 20:4 PE, with some samples were improved
by 500% or more. Certain patient samples that were negative or marginally positive by egg
PE showed strongly positive reactivity to 20:4 PE. Samples that were negative by 20:4 PE
J Immunol Methods. Author manuscript; available in PMC 2018 January 01.
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were also negative by egg PE. Overall, the current formulation of 20:4 PE consistently led to
a higher OD value than egg PE with P = 0.012 (n = 14).
The effect and optimization of synthetic phospholipid compositions on the ELISA
performance of cofactor-dependent aPE
We conducted screening studies using different synthetic PE compositions on the ELISA
performance for cofactor-dependent aPE. Figures 8A to C demonstrated the relative aPE
reactivity from representative cofactor-dependent aPE IgG, IgM and IgA, respectively. The
data indicated, somewhat unexpectedly, that a single species of 18:1 PE (Figures 8A to C,
formulation 4) was able to approach the reactivity level of egg PE. In addition, substitution
or dilution of 18:1 PE with other PE species (for example, 16:0, 18:0, 20:4 PE or 22:6 PE),
is more likely to result in a lower performance.
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In a head-to-head comparison with egg PE, we used 18:1 PE to test for detecting cofactordependent aPE reactivity of 12 patient serum samples, which included 3 IgM aPE, 8 IgG
aPE and 1 IgA aPE. The results (Figure 9) indicated that 18:1 PE delivered a similar
sensitivity as egg PE for detecting aPE reactivity, with a P value of 0.99.
Testing ELISA performance with synthetic PE species by using purified total IgG
In order to minimize uncertainties caused by potential confounding factors in the serum and
variations in immunoglobulin contents, the total IgG was isolated from representative aPE
patient serum samples and was used to validate the above findings in ELISA assays.
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Microplates were coated using Egg PE, 20:4 PE or 18:1 PE for IgG aPE ELISA for normal
human serum, a representative cofactor-dependent and cofactor-independent patient serum.
As shown in Figure 10, the cofactor-independent sample had significant reactivity against
egg PE and 20:4 PE, whereas the signal from 18:1 PE was near negligible. In contrast, for
the cofactor-dependent sample, there was apparent reactivity against egg PE and 18:1 PE,
but not 20:4 PE. To validate the difference in reactivity between 18:1 PE and 20:4 PE in
cofactor-dependent aPE, total IgG from two other cofactor-dependent aPE samples were
isolated, and their reactivity against egg PE, 20:4 PE, 18:1 PE and PS as a negative control
was tested. The ELISA results (Figure 11) indicated that again, the cofactor-dependent aPE
IgG sample strongly recognized egg PE and 18:1 PE, but not 20:4 PE or the negative control
PS. These findings were consistent with 20:4 PE being a preferred antigen for cofactorindependent IgG aPE, and that 18:1 PE is a preferred antigen for cofactor-dependent IgG
aPE. Additionally, the presence of ABP significantly diminished the reactivity of cofactorindependent aPE, suggesting that ABP may contain elements that potentially compete with
cofactor-independent aPE. Similar observations have been documented in prior reports (23).

Discussion
ELISA is the predominant method for detecting the presence of autoantibodies against PE.
Existing reports in the current literature, which employed different natural PE extracts,
indicated that the outcome of aPE ELISA may differ depending on the source of PE (6, 22,
23). These variations suggest that the composition and physicochemical properties of PE
antigens could have a significant impact on the reactivity of aPE antibodies. The term PE
J Immunol Methods. Author manuscript; available in PMC 2018 January 01.
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refers to a collection of species where, although they share the phosphorylethanolamine head
group as a common structural feature, they have different fatty acyl chains (25–30).
Relatively little is known about the actual impact in the variations of PE on the performance
of aPE ELISA. Such knowledge, when available, could shed light on the nature of
immunological reactivity of aPE and help develop standardized ELISA conditions using
synthetic components.
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The goal of the current study was to examine, using a series of synthetic positionally
symmetrical PE species, how the outcome of aPE ELISA may be dependent on differences
in PE. The phospholipids encompass a wide range of structural entities that vary in polarity,
charge, hydrophobicity, size and shape (24, 32–34). The diversity of their biological
functions is further enriched by controlled biosynthesis, compartmentalization and
trafficking (32–34). Phospholipids that are identified by the same headgroup can have
different species owing to properties of the acyl chains. These include differences in length,
degree of unsaturation and stereoisomerism of the fatty tails, as well as positional
asymmetry between sn-1 and sn-2 in the glycerol backbone (32–35). It is appreciated that in
biological membranes, the fatty acyl chains are mostly asymmetrical, adding yet another
layer of versatility to the membrane structure and functions (35). The PE species used in the
current study differed in length and the degree of unsaturation, but were positionally
symmetrical. While the latter was a choice made to limit the number of variables when
creating a simplified model system, it inevitably introduced limitations where positionally
symmetrical PE may not fully recapitulate the properties of naturally occurring biological
membranes. Nevertheless, key findings from these experiments were that single and mixed
synthetic PE species can indeed have a significant impact on the performance of aPE
ELISA. Additionally, for the first time, the present data demonstrated that cofactordependent and -independent aPE may have distinct epitope preferences. These findings may
open up new opportunities for adjusting aPE ELISA conditions with improved specificity
and shed light on the nature of antibody-antigen interactions in aPE. The current findings
warrant future studies using positionally asymmetrical PE species which, while introducing
another degree of complexity in terms of lipid properties, may better represent natural PE in
biological membrane systems.
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Our data support the notion that different fatty acid length and saturation level can strongly
influence the performance of aPE ELISA. For cofactor-independent IgM aPE, highly
unsaturated PE has better performance than lower degrees of unsaturated PE and saturated
PE; a longer fatty acid chain is preferred over a shorter one when comparing single PE
species. The combination of one saturated and one unsaturated PE is comparable or better
than either of the single species. Mixtures of multiple PE species at the right compositions
may achieve an even higher performance, which allowed us to fine-tune the composition for
optimization. These observations indicated that for cofactor-independent IgM aPE, the
complexity of antigen combination may be important. It is possible that this complexity
reflects specific solid/liquid phases that facilitate the interactions with IgM aPE.
Somewhat unexpectedly, the data revealed that cofactor-independent IgG aPE was
preferentially reactive to 20:4 PE, whereas cofactor-dependent aPE was more selective for
18:1 PE. It indicated that different aPE antibodies may have distinct PE requirements. From
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a lipid physics perspective, the relative hydrodynamic size of the head group versus the fatty
acid tails plays a predominant role in dictating the shape of individual lipid molecules,
which in turn, contributes to the structure of the lipid membrane (36). The
phosphorylethanolamine head group in PE is relatively small. In the presence of bulky fatty
acid tails, PE assumes an inverted cone shape, which favors hexagonal structures at
physiological temperatures. Consistent with the shape-structure hypothesis, PE species with
longer polyunsaturated fatty acids tend to form hexagonal tubes with smaller diameters (37,
38). This relationship has been demonstrated using electron microscopy with freezefractured lipid preparations (37). Without knowing the specific antigenic epitope(s) for aPE,
these structural differences in the physical organization of PE membranes may offer clues in
the preferential reactivity of aPE antibodies and cofactors to different PE species. In terms of
making diagnostics for aPE, the ability to distinctly test for the presence of cofactordependent and -independent reactivity may help differentiate different forms of aPE and
reduce ambiguity.
It is of interest to note that cofactor-independent IgM and IgG do not share a specific
antigenic feature, where the former prefers longer fatty acids with a greater degree of
unsaturation but the latter binds optimally to 20:4 PE. In contrast, among cofactor-dependent
isotypes including IgM, IgG and IgA, there appears to be a common factor as the 18:1 PE.
Relatively high levels of aPE reactivity could be consistently achieved when 18:1 PE was the
sole or dominant component in the antigen composition. Reduction or substitution of 18:1
PE can be associated with significantly diminished aPE performance. A limitation for the
current investigation is that only a relatively small number of serum samples were tested.
Future studies involving larger cohorts are likely to provide further evidence on this
observation.
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The present data demonstrated that factors other than PE antigens could also have a
significant impact on ELISA performance. The data showed that while the presence of ABP
was necessary to produce a positive reactivity for cofactor-dependent aPE, its presence was
consistently associated with a diminished ELISA reactivity for cofactor-independent aPE.
Further evidence is warranted in order to determine, conclusively, whether this reduction
was due to a competitive nature of ABP. A similar observation has been made in a prior
report that the phospholipid contents in ABP were greater than fetal calf serum, and could
have been a contributing factor that depletes aPE antibodies thus diminishes ELISA
reactivity (23). As an alternative explanation, a PE-binding factor could sequester and
competitively mask the antigen, thus prevents antibody-antigen interactions. Existing
literature has identified the kininogens as PE-binding cofactors in at least a portion of
cofactor-dependent aPE cases (39). It would be of interest to determine, in future studies,
whether the kininogens or other unknown factors may indeed interact with PE species that
have a specific physicochemical characteristic.
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The ELISA performance, relative to that of egg PE, of single and combinations of synthetic
PE species using a representative IgM aPE patient plasma. The formulations are specified as
follows.
(1) Egg PE;
(2) 16:0 PE;
(3) 18:0 PE;
(4) 18:1 PE;
(5) 20:4 PE;
(6) 22:6 PE;
(7) 30% 16:0 PE and 70% 18:1PE;
(8) 30% 16:0 PE and 70% 20:4 PE;
(9) 30% 16:0 PE and 70% 22:6 PE;
(10) 30% 18:0 PE and 70% 18:1PE;
(11) 30% 18:0 PE and 70% 20:4 PE;
(12) 30% 18:0 PE and 70% 22:6 PE;
(13) 15% 16:0 PE, 15% 18:0 PE, 17.5% 18:1 PE and 52.5% 20:4 PE;
(14) 15% 16:0 PE, 15% 18:0 PE, 23.3% 18:1 PE and 46.7% 20:4 PE;
(15) 20% 16:0 PE, 10% 18:0 PE, 15.75% 18:1 PE, 47.25% 20:4 PE; and 7% 22:6 PE;
(16) 20% 16:0 PE, 10% 18:0 PE, 21% 18:1 PE and 42% 20:4 PE and 7% 22:6 PE.
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A total of 0.5 µg indicated PE was coated on each well of a 96 plate. OD405 was measured,
subtracted of normal control value, and normalized to the reactivity of egg PE. The results
were obtained from triplicates.

Author Manuscript
Author Manuscript
Author Manuscript
J Immunol Methods. Author manuscript; available in PMC 2018 January 01.

Hou et al.

Page 14

Author Manuscript
Author Manuscript
Author Manuscript

Figure 2.

Author Manuscript

Testing for optimal phospholipid combinations for cofactor-independent IgM aPE ELISA
using a representative IgM aPE patient plasma. The formulations are specified as follows.
(1) egg PE;
(2) 0% 18:0 PE, 16.6% 18:1 PE, 33.2% 20:4 PE, and 49.8% 22:6 PE;
(3) 10% 18:0 PE, 15% 18:1 PE, 30% 20:4 PE, and 45% 22:6 PE;
(4) 20% 18:0 PE, 13.3% 18:1 PE, 26.6% 20:4 PE, and 39.9% 22:6 PE;
(5) 30% 18:0 PE, 11.6% 18:1 PE, 23.2% 20:4 PE, and 34.8% 22:6 PE;
(6) 40% 18:0 PE, 10% 18:1 PE, 20% 20:4 PE, and 30% 22:6 PE;
(7) 60% 18:0 PE, 6.6% 18:1 PE, 13.2% 20:4 PE, and 19.8% 22:6 PE;
(8) 80% 18:0 PE, 3.3% 18:1 PE, 6.6% 20:4 PE, and 9.9% 22:6 PE;
(9) 0% 18:0 PE, 16.6% 18:1 PE,49.8% 20:4 PE, and 33.2% 22:6 PE;
(10) 10% 18:0 PE, 15% 18:1 PE, 45% 20:4 PE, and 30% 22:6 PE;
(11) 20% 18:0 PE, 13.3% 18:1 PE, 39.9% 20:4 PE, and 26.6% 22:6 PE;
(12) 30% 18:0 PE, 11.6% 18:1 PE, 34.8% 20:4 PE, and 23.2% 22:6 PE;
(13) 40% 18:0 PE, 10% 18:1 PE, 30% 20:4 PE, and 20% 22:6 PE;
(14) 60% 18:0 PE, 13.2% 18:1 PE, 6.6% 20:4 PE, and 19.8% 22:6 PE;
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(15) 80% 18:0 PE, 3.3% 18:1 PE, 9.9% 20:4 PE, and 6.6% 22:6 PE.
A total of 0.5 µg of indicated PE was coated on each well of a 96 plate. OD405 was
measured, subtracted of normal control value, and normalized to the reactivity of egg PE.
The results were obtained from triplicates.
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Figure 3.
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Characterizing the impact of unsaturated PE species on aPE ELISA performance for
cofactor-independent IgM aPE using a representative IgM aPE patient plasma. The
formulations are specified as follows.
(1) egg PE;
(2) 20% 18:0 PE, 33.3% 18:1 PE, 33.3% 20:4 PE, and 33.3% 22:6 PE;
(3) 20% 18:0 PE, 20% 18:1 PE, 60% 20:4 PE, and 0% 22:6 PE;
(4) 20% 18:0 PE, 20% 18:1 PE, 0% 20:4 PE, and 60% 22:6 PE;
(5) 20% 18:0 PE, 13.3% 18:1 PE, 66.5% 20:4 PE, and 0% 22:6 PE;
(6) 20% 18:0 PE, 13.3% 18:1 PE, 0% 20:4 PE, and 66.5% 22:6 PE;
(7) 20% 18:0 PE, 13.3% 18:1 PE, 26.6% 20:4 PE, and 39.9% 22:6 PE;
(8) 20% 18:0 PE, 13.3% 18:1 PE, 39.9% 20:4 PE, and 26.6% 22:6 PE;
(9) 10% 18:0 PE, 30% 18:1 PE,30% 20:4 PE, and 30% 22:6 PE;
(10) 10% 18:0 PE, 22.5% 18:1 PE, 67.5% 20:4 PE, and 0% 22:6 PE;
(11) 10% 18:0 PE, 22.5% 18:1 PE, 0% 20:4 PE, and 67.5% 22:6 PE;
(12) 10% 18:0 PE, 15% 18:1 PE, 75% 20:4 PE, and 0% 22:6 PE;
(13) 10% 18:0 PE, 15% 18:1 PE, 0% 20:4 PE, and 75% 22:6 PE;
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(14) 10% 18:0 PE, 15% 18:1 PE, 30% 20:4 PE, and 45% 22:6 PE;
(15) 10% 18:0 PE, 15% 18:1 PE, 45% 20:4 PE, and 30% 22:6 PE.
A total of 0.5 µg of indicated PE was coated on each well of a 96 plate. OD405 was
measured, subtracted of normal control value, and normalized to the reactivity of egg PE.
The results were obtained from triplicates.
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Determination of the amount of PE coating and its impact on ELISA. The indicated amount
of PE was coated on a 96 well plate and aPE ELISA was performed. The results were
obtained from triplicates. A) Egg PE. B) 20% 18:0 PE, 13.3% 18:1 PE, 39.9% 20:4 PE, and
26.6% 22:6 PE.
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Figure 5.

A head-to-head comparison on the ELISA performance between egg PE and the current kit
formulation using cofactor-independent IgM plasma samples. The ELISA plate was coated
with 0.5 µg of egg PE or the kit formulation (20% 18:0 PE, 13.3% 18:1 PE, 39.9% 20:4 PE,
and 26.6% 22:6 PE). OD405 was measured after ELISA and the OD value from the normal
human serum was subtracted. The net value was the mean of triplicates. A total 11 patient
plasma samples were tested. P = 0.006.
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Screening of synthetic PE formulations for detecting cofactor-independent aPE IgG using a
representative IgG aPE patient plasma. Formulations are specified as follows. The 20:4 PE
was identified as a preferred antigen.
(1) Egg PE;
(2) 16:0 PE;
(3) 18:0 PE;
(4) 18:1 PE;
(5) 20:4 PE;
(6) 22:6 PE;
(7) 20% 16:0 PE and 80% 18:1PE;
(8) 20% 16:0 PE and 80% 20:4 PE;
(9) 20% 16:0 PE and 80% 22:6 PE;
(10) 20% 18:0 PE and 80% 18:1PE;
(11) 20% 18:0 PE and 80% 20:4 PE;
(12) 20% 18:0 PE and 80% 22:6 PE;
(13) 10% 16:0 PE, 10% 18:0 PE, 13.3% 18:1 PE, 26.6% 20:4 PE and 39.9% 22:6 PE;
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(14) 10% 16:0 PE, 10% 18:0 PE, 13.3% 18:1 PE, 39.9% 20:4 PE and 26.6% 22: PE;
(15) 20% 16:0 PE, 10% 18:0 PE, 13.3% 18:1 PE, 26.6% 20:4 PE and 39.9% 22:6 PE;
(16) 20% 18:0 PE, 13.3% 18:1 PE, 39.9% 20:4 PE and 26.6% 22:6 PE.
A total of 1 µg indicated PE was used to coat each well of a 96 plate. OD405 was measured,
subtracted of normal control value, and normalized to the reactivity of egg PE. The results
were obtained from triplicates.
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Figure 7.

Head-to-head comparison between egg PE and synthetic 20:4 PE on the ELISA for cofactorindependent IgG aPE. Each well of a 96 well plate was coated with 1 µg of indicated PE.
OD405 was measured after ELISA and was subtracted of normal control value. The values
are the means of triplicates. A total 14 patient serums were tested. P = 0.012.
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Figure 8.

Screening of phospholipid combinations for ABP-dependent aPE using representative IgG,
IgM and IgA aPE patient plasma samples. The 18:1 PE was identified as preferred antigen.
Individual formulas are specified as follows.
(1) Egg PE;
(2) 16:0 PE;
(3) 18:0 PE;
(4) 18:1 PE;
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(5) 20:4 PE;
(6) 22:6 PE;
(7) 20% 16:0 PE and 80% 18:1PE;
(8) 20% 16:0 PE and 80% 20:4 PE;
(9) 20% 16:0 PE and 80% 22:6 PE;
(10) 20% 18:0 PE and 80% 18:1PE;
(11) 20% 18:0 PE and 80% 20:4 PE;
(12) 20% 18:0 PE and 80% 22:6 PE;
(13) 10% 16:0 PE, 10% 18:0 PE, 13.3% 18:1 PE, 26.6% 20:4 PE and 39.9% 20:6 PE;
(14) 10% 16:0 PE, 10% 18:0 PE, 13.3% 18:1 PE and 39.9% 20:4 PE and 26.6% 20:4 PE;
(15) 20% 16:0% 18:0 PE, 13.3% 18:1 PE, 26.6% 20:4 PE and 39.9% 22:6 PE;
(16) 20% 18:0 PE, 13.3% 18:1 PE, 39.9% 20:4 PE and 26.6% 22:6 PE.
A total of 1 µg indicated PE was used to coat each well of a 96 plate. OD405 was measured,
subtracted of normal control value, and normalized to the reactivity of egg PE. The results
were obtained from triplicates.
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Figure 9.

A head-to-head comparison between egg PE and 18:1 PE on the ELISA for cofactordependent aPE samples. One µg indicated PE was used to coat each well of a 96 plate.
OD405 was measured, subtracted of normal control value, and normalized to the reactivity of
egg PE. The values are means of triplicates. A total of 12 patient plasma samples were used,
including 8 IgG aPE, 3 IgM aPE and 1 IgA aPE. P = 0.9989.
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Figure 10.

aPE reactivity to egg PE, 20:4 PE and 18:1 PE using affinity-purified total IgG from a
cofactor-dependent and a cofactor-independent IgG aPE patient plasma. For each ELISA
test, the total IgG was used at a concentration of 200 µg/ml. The data demonstrated that the
cofactor-dependent and cofactor-independent IgG aPE prefer 18:1 PE and 20:4 PE,
respectively. The values are means of triplicates.
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Figure 11.

aPE activity to synthetic PE antigens using affinity purified total IgG from two different
patients with cofactor-dependent IgG aPE. The data demonstrated a preference to 18:1 PE as
an antigen. The values are means of triplicates.
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